Search | Clinical Trials Finder

Conditions: Glaucoma, Ocular Hypertension
Interventions: fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution; bimatoprost 0.03% ophthalmic solution, bimatoprost 0.03% ophthalmic solution; hypromellose 0.2% eyedrops; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Glaucoma, Ocular Hypertension
Interventions: bimatoprost /timolol formulation A fixed combination ophthalmic solution, bimatoprost/timolol fixed combination ophthalmic solution; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 561 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Artesia, California

Conditions: Hypotrichosis
Interventions: Bimatoprost 0.03% solution, Vehicle solution; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 368 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: San Diego, California

Conditions: Open-Angle Glaucoma, Ocular Hypertension
Interventions: bimatoprost 20 µg generation 2, bimatoprost 15 µg generation 2, bimatoprost 10 µg generation 2, bimatoprost 6 µg generation 2, bimatoprost 15 µg generation 1, bimatoprost 10 µg generation 1, bimatoprost 0.03%; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 36
States / cities: Artesia, California • La Jolla, California • Los Angeles, California + 31 more

Conditions: Glaucoma, Ocular Hypertension
Interventions: Bimatoprost 0.03% Formulation B Ophthalmic Solution, Bimatoprost 0.03% Ophthalmic Solution; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 597 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Alopecia Areata
Interventions: Latanoprost (Xalatan), Bimatoprost (Lumigan), Topical application of latanoprost solution to eyelid; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 70 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Glaucoma, Open-Angle, Ocular Hypertension
Interventions: AGN-210669, bimatoprost, bimatoprost vehicle; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Ocular Hypertension, Glaucoma
Interventions: bimatoprost 0.03% eye drops, latanoprost 0.005% eye drops; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 586 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Eyelashes
Interventions: Bimatoprost 0.03% sterile solution, vehicle sterile solution; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 278 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: San Diego, California

Conditions: Glaucoma, Ocular Hypertension
Interventions: Bimatoprost 0.01% ophthalmic solution, Bimatoprost 0.015% formulation 1 ophthalmic solution, Bimatoprost 0.015% formulation 2 ophthalmic solution, Bimatoprost 0.02% ophthalmic solution, Bimatoprost 0.03% ophthalmic solution; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 249 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005
U.S. locations: 1
States / cities: Wenatchee, Washington

Conditions: Hypotrichosis
Interventions: bimatoprost ophthalmic solution 0.03%, bimatoprost vehicle solution; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Coral Gables, Florida

Conditions: Ocular Hypertension, Primary Open-Angle Glaucoma
Interventions: AGN-210961 Formulation 1, AGN-210961 Formulation 2, AGN-210961 Formulation 3, AGN-210961 Formulation 4, AGN-210961 Formulation 5, AGN-210961 Formulation 6, AGN-210961 Formulation 7, bimatoprost ophthalmic solution 0.03%; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 163 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Hypotrichosis
Interventions: bimatoprost ophthalmic 0.03% solution, vehicle sterile solution (placebo); Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Eyelash Hypotrichosis
Interventions: bimatoprost ophthalmic solution 0.005%, bimatoprost ophthalmic solution 0.015%, bimatoprost ophthalmic solution 0.03%; Drug
Lead sponsor: Allergan; Industry
Eligibility: 30 Years to 55 Years · Female only
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: San Diego, California

Conditions: Cataract
Interventions: Bimatoprost 0.03%; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 4
States / cities: Indianapolis, Indiana

Conditions: Glaucoma, Open-Angle, Ocular Hypertension
Interventions: AGN-210669 ophthalmic solution, 0.1%, AGN-210669 ophthalmic solution, 0.075%, AGN-210669 ophthalmic solution, 0.05%, bimatoprost ophthalmic solution 0.03%; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Glaucoma, Application Site Pigmentation Changes
Interventions: latanoprost, bimatoprost, travoprost; Drug
Lead sponsor: Summa Health System; Other
Eligibility: 30 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 2
States / cities: Arlington Heights, Illinois • Akron, Ohio

Conditions: Idiopathic Eyelash Hypotrichosis
Interventions: bimatoprost formulation A solution, bimatoprost solution 0.03 %, vehicle of bimatoprost formulation A solution, vehicle of bimatoprost solution 0.03 %; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 464 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Eyelash Hypotrichosis, Alopecia Areata
Interventions: bimatoprost ophthalmic solution 0.03%, Vehicle Sterile Solution; Drug
Lead sponsor: Allergan; Industry
Eligibility: 5 Years to 17 Years
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Glaucoma, Ocular Hypertension
Interventions: Bimatoprost 0.01% Ophthalmic Solution, Bimatoprost 0.03% Ophthalmic Solution, Bimatoprost Vehicle Ophthalmic Solution; Drug
Lead sponsor: Allergan; Industry
Eligibility: 20 Years and older
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Ocular Hypertension, Glaucoma
Interventions: AGN-210669 ophthalmic solution, 0.075%, AGN-210669 ophthalmic solution, 0.05%, AGN-210669 ophthalmic solution, 0.025%, bimatoprost ophthalmic solution 0.03%, AGN-210669 vehicle ophthalmic solution; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 172 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Artesia, California

Conditions: Glaucoma, Ocular Hypertension
Interventions: bimatoprost 0.03% eye drops, travoprost 0.004% eye drops; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 266 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: San Diego, California

Conditions: Open-angle Glaucoma, Ocular Hypertension
Interventions: High Dose Drug Device, Low Dose Drug Device, Placebo Device, bimatoprost 0.03%; Drug
Lead sponsor: Vistakon Pharmaceuticals; Industry
Eligibility: 21 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 5
States / cities: Miami, Florida • Philadelphia, Pennsylvania • Mt. Pleasant, South Carolina + 2 more

Conditions: Dermatochalasis
Interventions: bimatoprost 0.03% ophthalmic solution; Drug
Lead sponsor: Tulane University; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: New Orleans, Louisiana

Search by objective public record fields.

Comparing Safety and Efficacy of Combigan® and Lumigan® With Lumigan® Alone in Glaucoma or Ocular Hypertension Subjects Treated With Xalatan®

Safety and Efficacy of a New Formulation of Bimatoprost/Timolol Ophthalmic Solution Compared With Bimatoprost/Timolol Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

Safety and Efficacy Study of Bimatoprost to Treat Hypotrichosis of the Eyelashes After Application to the Eyelid Margin

Safety and Efficacy of a New Ophthalmic Formulation of Bimatoprost in Patients With Open Angle Glaucoma and Ocular Hypertension

Safety and Efficacy of Different Formulations of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

Efficacy Study of Latanoprost and Bimatoprost Solutions in Promoting Eyelash Growth in Patients With Alopecia Areata

Safety and Efficacy of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Open-Angle Glaucoma or Ocular Hypertension

Safety and Efficacy of Bimatoprost Compared With Latanoprost in Patients With Glaucoma or Ocular Hypertension

Safety and Efficacy of Bimatoprost Solution in Increasing Overall Eyelash Prominence

Safety and Efficacy Study of Different Formulations of Bimatoprost Once-Daily in Patients With Glaucoma or Ocular Hypertension

Study Assessing Patient Satisfaction With LATISSE® for Increasing Eyelash Prominence

Safety and Efficacy of AGN-210961 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

Study of Bimatoprost Solution in Increasing Eyelash Prominence in African Americans With Eyelash Hypotrichosis

Safety and Efficacy of Bimatoprost Ophthalmic Solution in Increasing Eyelash Prominence

Bioavailability of Bimatoprost Ophthalmic Solution in Human Aqueous.

Safety and Efficacy of Three Formulations of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution

The Effects of Xalatan, Travatan and Lumigan on Skin Pigmentation Near the Eye

Bimatoprost in the Treatment of Eyelash Hypotrichosis

Safety and Efficacy of Bimatoprost Solution in Treating Eyelash Loss or Hypotrichosis in Children

Safety and Efficacy Study of Bimatoprost in Ethnically Japanese Patients With Open-Angle Glaucoma or Ocular Hypertension

Safety and Efficacy of AGN 210669 Ophthalmic Solution in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma

Bimatoprost 0.03% Versus Travoprost 0.004% in Patients Currently on Latanoprost 0.005%

Safety and Efficacy of a Drug Delivery System in Glaucoma

Topical Bimatoprost for Chemical Blepharoplasty